

Special Issue

Endometrial Stem/Progenitor Cell Biology: Prospects and Challenges

Message from the Guest Editors

Several types of endometrial stem/progenitor cells have been identified: endometrial mesenchymal stem cells, endometrial epithelial progenitor cells and side population cells comprising a heterogeneous population, predominantly endothelial cells. This Special Issue aims to highlight the challenges in endometrial stem/progenitor cell research, the application of endometrial stem/progenitor cells as a cell-based therapy for treating disorders will be welcomed. Areas to be covered in this Special Issue may include but are not limited to: recent evidence of cell-based therapies utilising endometrial derived mesenchymal stem cells, endometrial epithelial progenitors, topics including endometrial clonal evolution, mutation burden, 3D histoarchitecture, endometrial epithelial organoids and single cell sequencing which may have important relevance to endometrial stem/ progenitor cell biology and application in personalised medicine. Contributions by experts in the field, in the form of original research papers and reviews are most welcome.

Guest Editors

Prof. Caroline E. Gargett

Hudson Institute of Medical Research, The Ritchie Centre, Clayton, Australia

Prof. Dharani Hapangama

Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool Women's Hospital, Crown Street, Liverpool L8 7SS, UK

Deadline for manuscript submissions

closed (20 September 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/56131

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).